Alx Accounts Payable vs Other Stockholder Equity Analysis
ALXO Stock | USD 1.44 0.07 4.64% |
Alx Oncology financial indicator trend analysis is way more than just evaluating Alx Oncology Holdings prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alx Oncology Holdings is a good investment. Please check the relationship between Alx Oncology Accounts Payable and its Other Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
Accounts Payable vs Other Stockholder Equity
Accounts Payable vs Other Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alx Oncology Holdings Accounts Payable account and Other Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between Alx Oncology's Accounts Payable and Other Stockholder Equity is 0.74. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Alx Oncology Holdings, assuming nothing else is changed. The correlation between historical values of Alx Oncology's Accounts Payable and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Alx Oncology Holdings are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Accounts Payable i.e., Alx Oncology's Accounts Payable and Other Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.74 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Accounts Payable
An accounting item on the balance sheet that represents Alx Oncology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Alx Oncology Holdings are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Other Stockholder Equity
Most indicators from Alx Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alx Oncology Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. At this time, Alx Oncology's Issuance Of Capital Stock is very stable compared to the past year. As of the 12th of December 2024, Sales General And Administrative To Revenue is likely to grow to 11.84, while Tax Provision is likely to drop 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 83.6M | 127.4M | 170.3M | 178.8M | Cost Of Revenue | 736K | 1.5M | 836K | 1.4M |
Alx Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Alx Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alx Oncology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.7M | 436.1M | 380.2M | 306.5M | 242.6M | 254.3M | |
Other Current Liab | 1.2M | 6.0M | 10.8M | 19.2M | 25.8M | 27.1M | |
Total Current Liabilities | 5.0M | 6.2M | 15.3M | 28.3M | 36.0M | 37.8M | |
Total Stockholder Equity | (276K) | (118.5M) | (202.0M) | (325.5M) | 189.7M | 199.2M | |
Other Liab | 547K | 5K | 1.8M | 53K | 61.0K | 57.9K | |
Net Tangible Assets | (70.6M) | 429.8M | 363.0M | 263.5M | 303.0M | 205.5M | |
Property Plant And Equipment Net | 860K | 52K | 3.5M | 9.8M | 10.8M | 11.4M | |
Net Debt | (3.6M) | (434.2M) | (362.9M) | (272.5M) | (5.2M) | (5.5M) | |
Retained Earnings | (72.8M) | (118.5M) | (202.0M) | (325.5M) | (486.3M) | (462.0M) | |
Accounts Payable | 3.7M | 4K | 3.8M | 8.1M | 8.6M | 4.6M | |
Cash | 9.0M | 434.2M | 363.7M | 282.9M | 22.4M | 21.3M | |
Non Current Assets Total | 867K | 1.8M | 13.2M | 35.5M | 53.9M | 56.6M | |
Cash And Short Term Investments | 9.0M | 434.2M | 363.7M | 282.9M | 182.7M | 234.8M | |
Common Stock Shares Outstanding | 36.5M | 39.8M | 40.3M | 40.7M | 43.0M | 40.8M | |
Liabilities And Stockholders Equity | 10.7M | 436.1M | (184.9M) | (282.4M) | 242.6M | 254.7M | |
Non Current Liabilities Total | 6.0M | 5K | 1.8M | 14.7M | 16.8M | 17.7M | |
Capital Surpluse | 2.1M | 548.3M | 565.0M | 589.7M | 678.2M | 375.5M | |
Other Current Assets | 256K | 3.5M | 6.7M | 4.8M | 5.9M | 4.1M | |
Other Stockholder Equity | 2.1M | 548.3M | 565.0M | 589.7M | 675.7M | 437.0M | |
Total Liab | 11.0M | 436.1M | 17.1M | 43.0M | 52.8M | 74.9M | |
Net Invested Capital | (65.2M) | 429.8M | 363.0M | 272.9M | 199.4M | 210.5M | |
Property Plant And Equipment Gross | 860K | 52K | 3.5M | 10.2M | 12.1M | 12.7M | |
Total Current Assets | 9.8M | 434.2M | 367.0M | 271.0M | 188.7M | 234.8M | |
Accumulated Other Comprehensive Income | (1.4M) | (554.6M) | 0.0 | (845K) | 256K | 268.8K | |
Net Working Capital | 4.8M | 429.8M | 351.7M | 242.6M | 152.7M | 218.2M | |
Property Plant Equipment | 860K | 52K | 897K | 3.9M | 4.5M | 4.7M |
Pair Trading with Alx Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Alx Stock
0.72 | BMY | Bristol Myers Squibb | PairCorr |
0.68 | GILD | Gilead Sciences | PairCorr |
0.43 | FLGC | Flora Growth Corp | PairCorr |
0.38 | ESPR | Esperion Therapeutics | PairCorr |
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.97) | Quarterly Revenue Growth (1.00) | Return On Assets (0.49) | Return On Equity (0.99) |
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.